Skip to content
Screener

Alkermes ALKS Operating Lease Liabilities

Operating Lease Liabilities at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$47.3M+22.0%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$22.39M-6.4%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$14M-53.3%
LBR
LB Pharmaceuticals IncLBRX
$2.74M
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$262.48M+59.7%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$406.2M-9.2%

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.11B+85.1%
Enterprise value$9.18B+133%
P/E122.7×+110×
P/S4.9×+2.0×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemJune 30, 2026December 31, 2025
Operating lease liabilities—short-term7,4776,746
Current portion of long-term debt26,500
Total current liabilities662,091543,437
OPERATING LEASE LIABILITIES—LONG-TERM61,97663,253
CONTINGENT CONSIDERATION136,304
LONG-TERM DEBT1,476,611
DEFERRED TAX LIABILITIES179,575
OTHER LONG-TERM LIABILITIES68,01861,008

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's operating lease liabilities?
Alkermes (ALKS) reported operating lease liabilities of $61.98M in Q2 2026.
How has Alkermes's operating lease liabilities changed year-over-year?
Alkermes's operating lease liabilities decreased by 6.4% year-over-year, from $66.22M to $61.98M.
What is the long-term trend for Alkermes's operating lease liabilities?
Over 5 years (2020 to 2025), Alkermes's operating lease liabilities has grown at a -11.9% compound annual growth rate (CAGR), from $119.46M to $63.25M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.

Ask your AI about Alkermes's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude